Drug Trial Radar · NCT02273375
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,415
Actual
Start
Feb 24, 2015
Primary completion
Jul 23, 2025
Study completion Sep 1, 2026
Sponsor
- Lead sponsor
- Canadian Cancer Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- Intergroupe Francophone de Cancerologie Thoracique; Thoracic Oncology Group of Australasia (TOGA); National Health and Medical Research Council, Australia; National Cancer Institute, Naples; Central and Eastern European Oncology Group; Dutch Society of Physicians for Pulmonology and Tuberculosis; Korean Cancer Study Group; Fundación GECP; West Japan Oncology Group; Chinese Thoracic Oncology Group
- First posted
- Oct 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
Conditions
- Non-Small Cell Lung Cancer
Interventions
MEDI4736Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare Disease Free Survival (DFS) for Patients With NSCLC That is PD-L1 Expression TC ≥ 25% and Patients Without EGFR Exon 21 L858R Mutation or Exon 19 Deletions or ALK Gene RearrangementsTime frame: Up to 8.3 years
Locations
271 sites in 19 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
USC Norris/Comprehensive Cancer Centre
Los Angeles, California
National Jewish Health
Denver, Colorado
University of Florida
Gainesville, Florida
H. Lee Moffitt Cancer Center
Tampa, Florida
Duke University Medical Center
Durham, North Carolina
Hematology and Oncology Associates of NEPA
Dunmore, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
The Reading Hospital Medical Center
West Reading, Pennsylvania
Flinders Medical Center
Adelaide, Australia
Canberra Hospital
Garran, Australia
Campbelltown Hospital
Campbelltown, New South Wales, Australia
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Coffs Habour Health Campus - NCCI
Coffs Harbour, New South Wales, Australia
Gosford Hospital
Gosford, New South Wales, Australia
Nepean Hospital
Kingswood, New South Wales, Australia
St. George Hospital, Cancer Care Centre
Kogarah, New South Wales, Australia
Liverpool Cancer Therapy Centre, Liverpool Hospital
Liverpool, New South Wales, Australia
Northern Cancer Institute St Leonards
St Leonards, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Princess Alexandra Hospital
Brisbane, Queensland, Australia
The Prince Charles Hospital
Chermside, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Mater Medical Centre
Brisbane, South, QLD, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Frankston Hospital - Peninsula Oncology Centre
Frankston, Victoria, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Royal Melbourne Hospital Research Foundation
Parkville, Victoria, Australia
Epworth HealthCare - Richmond
Richmond, Victoria, Australia
Border Medical Oncology
Wodonga, Victoria, Australia
St. Vincent's Hospital
Victoria Park, Victoria Park, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia
St John of God Subiaco
Subiaco, Western Australia, Australia
Suporte Nutricional e Quimioterapia LTDA PRONUTRIR
Fortaleza, Ceará, Brazil
Hospital Evangelico de Cachoeiro de Itapemirim
Cachoeiro de Itapemirim, Espírito Santo, Brazil
Cetus Hospital Dia Oncologia
Belo Horizonte, Minas Gerais, Brazil
Instituto Nacional de Cancer (INCA)
Rio de Janeiro, Rio de Janeiro, Brazil
Showing 40 of 271 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.